Immune Pharmaceuticals Initiates Phase 2 Clinical Trial with Bertilimumab for Ulcerative Colitis Treatment

Immune Pharmaceuticals Initiates Phase 2 Clinical Trial with Bertilimumab for Ulcerative Colitis Treatment
Immune Pharmaceuticals, Inc. recently announced the enrollment of the first patient in its Phase 2 clinical trial to assess the safety and efficacy of the first-in-class, entirely human monoclonal antibody bertilimumab for the treatment of ulcerative colitis (UC). "We recently announced U.S. IND [Investigational New Drug] acceptance by the FDA for bertilimumab in bullous pemphigoid, and today, with our first patient enrollment in ulcerative colitis, this represents an important development for our lead product, bertilimumab. We intend to include leading academic medical centers globally, to support the timely completion of our two Phase 2 clinical trials," explained Dr. Daniel Teper, Immune Pharmaceuticals’ CEO, in a
Subscribe or to access all post and page content.